The Effectiveness and Value of Oral Immunotherapy and Viaskin Peanut for Peanut Allergy

Tice, Jeffrey A.; Guzauskas, Gregory F.; Hansen, Ryan N.; Herron-Smith, Serina; Segel, Celia; Walsh, Judith M. E.; Pearson, Steven D.

doi:10.18553/jmcp.2020.26.5.620

Cited by 7 publications

(5 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the past, food allergy cost-utility analyses had to rely on utility estimates from generic questionnaires or direct elicitation approaches that had not been validated in the food allergic population to estimate utility values for their models and the health state utility value for desensitized patients was somewhat arbitrarily defined. 8,[30][31][32][33][34] The new conversion algorithm will allow to directly as- Recently, Chen et al mapped the FAQLQ-PF to the AQoL-6D in parents of children aged 7-17 years. 26 The SF-6Dv2 and AQoL-6D…”

Section: Discussionmentioning

confidence: 99%

“…In the past, food allergy cost‐utility analyses had to rely on utility estimates from generic questionnaires or direct elicitation approaches that had not been validated in the food allergic population to estimate utility values for their models and the health state utility value for desensitized patients was somewhat arbitrarily defined 8,30‐34 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Mapping the Food Allergy Quality of Life Questionnaire Parent Form onto the Short‐Form Six‐Dimensions version 2

Watts

Dufresne

Samaan

et al. 2021

Allergy

View full text Add to dashboard Cite

Background:The Food Allergy Quality of Life Questionnaire Parent Form (FAQLQ-PF) is the most widely used quality of life questionnaire in food allergy. The objective of this study was to develop a mapping algorithm to convert FAQLQ-PF scores into health state utilities. Methods:The Short-Form Six-Dimensions version 2 (SF-6Dv2) and FAQLQ-PF questionnaires were collected from an academic center oral immunotherapy referral cohort. Utility estimates were derived from the SF-6Dv2 using the food allergy preference set. Candidate mapping algorithm models were developed using seven regression methods starting from either the total average score, the average scores of each of the three domains or the individual item scores of FAQLQ-PF. The process was repeated twice, including only section A, common to all age groups, or including all age-applicable sections of the FAQLQ-PF. The mean absolute error (MAE) and root mean squared error (RMSE) were used to select the best fitting model. An independent cohort from a previous national online survey was used for external validation.Results: In the index cohort, 1000 of 1257 respondents had completed both questionnaires. The lowest MAE (0.0791) and RMSE (0.1020) were recorded when entering individual item scores in a categorical regression model. The model including only FAQLQ-PF section A was found to be most consistent when tested in the external validation cohort (n = 248) (MAE of 0.0898). Conclusion:The FAQLQ-PF was mapped onto SF-6Dv2 utilities with good predictive accuracy in two independent cohorts. This will enable calculation of health utility for cost-effectiveness analyses in food allergy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Mapping the Food Allergy Quality of Life Questionnaire Parent Form onto the Short‐Form Six‐Dimensions version 2

Watts

Dufresne

Samaan

et al. 2021

Allergy

View full text Add to dashboard Cite

show abstract

“…The results obtained showed that EPIT was safe and associated with a moderate response to treatment after 52 weeks, with a high adherence rate and significant changes in the immunological response (an increase in peanut-specific IgG 4 levels and IgG 4 /IgE ratios in peanut EPIT-treated participants, along with trends toward reduced basophil activation and peanut-specific Th2 cytokines). Another study performed with Viaskin Peanut (patch) in EPIT, which is under revision by the US FDA, has shown clinical effectiveness [ 99 ]. However, the efficacy and safety of these therapies continue under revision.…”

Section: Allergen-specific Treatmentsmentioning

confidence: 99%

New Insights in Therapy for Food Allergy

Mayorga

Palomares

Cañas

et al. 2021

Foods

View full text Add to dashboard Cite

Food allergy is an increasing problem worldwide, with strict avoidance being classically the only available reliable treatment. The main objective of this review is to cover the latest information about the tools available for the diagnosis and treatment of food allergies. In recent years, many efforts have been made to better understand the humoral and cellular mechanisms involved in food allergy and to improve the strategies for diagnosis and treatment. This review illustrates IgE-mediated food hypersensitivity and provides a current description of the diagnostic strategies and advances in different treatments. Specific immunotherapy, including different routes of administration and new therapeutic approaches, such as hypoallergens and nanoparticles, are discussed in detail. Other treatments, such as biologics and microbiota, are also described. Therefore, we conclude that although important efforts have been made in improving therapies for food allergies, including innovative approaches mainly focusing on efficacy and safety, there is an urgent need to develop a set of basic and clinical results to help in the diagnosis and treatment of food allergies.

show abstract

“…However, the annual cost‐effectiveness limits of these two therapies were $1,508 and $2,369, and their adverse events included systematic allergic reactions, need for epinephrine, and other side effects leading to discontinuation of therapy. 8 …”

Section: Introductionmentioning

confidence: 99%

Food allergy treatment value: Child caregiver and patient perspectives

Abdelwadoud

Eftekhari

Jaffee

et al. 2021

Pediatric Allergy Immunology

View full text Add to dashboard Cite

Background Food allergy is a major health problem that significantly impacts quality of life (QoL). There is growing focus to evaluate food allergy‐related QoL and treatment options’ value beyond the clinical effectiveness perspective by engaging patients and caregivers. We aimed to identify and prioritize outcomes important to food allergy parents of children and patients allergic to milk, egg, and/or peanut, to guide comparative effectiveness research (CER) that focuses on evaluating food allergy treatment decisions. Methods We conducted a modified 3‐round Delphi study to identify and derive consensus on priority treatment outcomes for parents of children and adult patients with diagnosed allergies to at least one of three major allergenic foods (milk, egg, and peanut) from across the United States. Results Round 1 yielded 44 statements for round 2, and 39 statements reached the agreement level for round 3 ranking. Statements were organized under 4 sections: 1) food allergy problems, 2) treatment experiences, 3) important treatment outcomes, and 4) value of different treatment options. Conclusion Food allergy parents and patients face several social, psychological, medical, healthcare, financial, food selection, and awareness challenges. The areas of consensus on important treatment outcomes revealed shared priority for reducing the risk of potentially fatal allergic reactions and having reliable treatments. The most valued treatment options reflect hope for permanent cure and fear of serious allergic reactions.

show abstract

The Effectiveness and Value of Oral Immunotherapy and Viaskin Peanut for Peanut Allergy

Cited by 7 publications

References 10 publications

Mapping the Food Allergy Quality of Life Questionnaire Parent Form onto the Short‐Form Six‐Dimensions version 2

Mapping the Food Allergy Quality of Life Questionnaire Parent Form onto the Short‐Form Six‐Dimensions version 2

New Insights in Therapy for Food Allergy

Food allergy treatment value: Child caregiver and patient perspectives

Contact Info

Product

Resources

About